371 related articles for article (PubMed ID: 37828541)
1. Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.
Richardson PJ; Smith DP; de Giorgio A; Snetkov X; Almond-Thynne J; Cronin S; Mead RJ; McDermott CJ; Shaw PJ
Transl Neurodegener; 2023 Oct; 12(1):47. PubMed ID: 37828541
[TBL] [Abstract][Full Text] [Related]
2. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Bouscary A; Quessada C; René F; Spedding M; Turner BJ; Henriques A; Ngo ST; Loeffler JP
Semin Cell Dev Biol; 2021 Apr; 112():82-91. PubMed ID: 33160824
[TBL] [Abstract][Full Text] [Related]
4. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
5. The pivotal role of JAK/STAT and IRS/PI3K signaling pathways in neurodegenerative diseases: Mechanistic approaches to polyphenols and alkaloids.
Kooshki L; Zarneshan SN; Fakhri S; Moradi SZ; Echeverria J
Phytomedicine; 2023 Apr; 112():154686. PubMed ID: 36804755
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.
Benveniste EN; Liu Y; McFarland BC; Qin H
J Interferon Cytokine Res; 2014 Aug; 34(8):577-88. PubMed ID: 25084174
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
8. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
9. Microglial TREM2 in amyotrophic lateral sclerosis.
Xie M; Zhao S; Bosco DB; Nguyen A; Wu LJ
Dev Neurobiol; 2022 Jan; 82(1):125-137. PubMed ID: 34874625
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
Karati D; Mahadik KR; Trivedi P; Kumar D
Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
[TBL] [Abstract][Full Text] [Related]
11. [The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
van de Laar MAFJ; Hoentjen F; Thio HB
Ned Tijdschr Geneeskd; 2019 Aug; 163():. PubMed ID: 31433146
[TBL] [Abstract][Full Text] [Related]
12. Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis.
Shibata N; Yamamoto T; Hiroi A; Omi Y; Kato Y; Kobayashi M
Neuropathology; 2010 Aug; 30(4):353-60. PubMed ID: 19925559
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a non-canonical JAK/STAT signaling pathway in the synthesis of the brain's major ion channels and neurotransmitter receptors.
Hixson KM; Cogswell M; Brooks-Kayal AR; Russek SJ
BMC Genomics; 2019 Aug; 20(1):677. PubMed ID: 31455240
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
17. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
Kalmar B; Lu CH; Greensmith L
Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
[TBL] [Abstract][Full Text] [Related]
18. ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis.
Jablonski M; Miller DS; Pasinelli P; Trotti D
Brain Res; 2015 May; 1607():1-14. PubMed ID: 25175835
[TBL] [Abstract][Full Text] [Related]
19. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
Deeb O; Nabulsi M
Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
[TBL] [Abstract][Full Text] [Related]
20. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Bechman K; Yates M; Galloway JB
Pharmacol Res; 2019 Sep; 147():104392. PubMed ID: 31401212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
